Summary of Study ST002860

This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench,, where it has been assigned Project ID PR001788. The data can be accessed directly via it's Project DOI: 10.21228/M8KX5C This work is supported by NIH grant, U2C- DK119886.


This study contains a large results data set and is not available in the mwTab file. It is only available for download via FTP as data file(s) here.

Perform statistical analysis  |  Show all samples  |  Show named metabolites  |  Download named metabolite data  
Download mwTab file (text)   |  Download mwTab file(JSON)   |  Download data files (Contains raw data)
Study IDST002860
Study TitleGlucose tracing in vehicle- and Enzalutamide-treated 16D prostate cancer cells (replicates 2 and 3)
Study SummaryIn this study, we sought to determine how Enzalutamide treatment alters metabolism in 16D prostate cancer cells (replicates 2 and 3).
University of California, Los Angeles
LaboratoryGoldstein Lab
Last NameGiafaglione
First NameJenna
Address610 Charles E Young Dr S, Los Angeles, CA, 90024, USA
Submit Date2023-09-12
Raw Data AvailableYes
Raw Data File Type(s)d
Analysis Type DetailGC-MS
Release Date2023-09-15
Release Version1
Jenna Giafaglione Jenna Giafaglione application/zip

Select appropriate tab below to view additional metadata details:


Project ID:PR001788
Project DOI:doi: 10.21228/M8KX5C
Project Title:MYC is a regulator of AR inhibition-induced metabolic requirements in prostate cancer
Project Summary:Advanced prostate cancers are treated with therapies targeting the androgen receptor (AR) signaling pathway. While many tumors initially respond to AR inhibition, nearly all develop resistance. It is critical to understand how prostate tumor cells respond to AR inhibition in order to exploit therapy-induced phenotypes prior to the outgrowth of treatment-resistant disease. Here, we comprehensively characterize the effect of AR blockade on prostate cancer metabolism using transcriptomics, metabolomics and bioenergetics approaches. The metabolic response to AR inhibition is defined by reduced glycolysis, robust elongation of mitochondria, and increased reliance on mitochondrial oxidative metabolism. We establish DRP1 activity and MYC signaling as mediators of AR blockade-induced metabolic phenotypes. Rescuing DRP1 phosphorylation after AR inhibition restores mitochondrial fission, while rescuing MYC restores glycolytic activity and prevents sensitivity to complex I inhibition. Our study provides new insight into the regulation of treatment-induced metabolic phenotypes and vulnerabilities in prostate cancer.
Laboratory:Goldstein Lab
Last Name:Giafaglione
First Name:Jenna
Address:610 Charles E Young Dr S, Los Angeles, CA, 90024, USA


Subject ID:SU002972
Subject Type:Cultured cells
Subject Species:Homo sapiens
Taxonomy ID:9606


Subject type: Cultured cells; Subject species: Homo sapiens (Factor headings shown in green)

mb_sample_id local_sample_id Treatment
SA30896420201211_LTEnza-210uM Enzalutamide
SA30896520201211_LTEnza-110uM Enzalutamide
SA30896620201210_LTEnza-310uM Enzalutamide
SA30896720201210_LTEnza-110uM Enzalutamide
SA30896820201210_LTEnza-210uM Enzalutamide
SA30896920201211_LTEnza-310uM Enzalutamide
SA30897020201211_Naive-3Vehicle (DMSO)
SA30897120201211_Naive-1Vehicle (DMSO)
SA30897220201210_Naive-2Vehicle (DMSO)
SA30897320201210_Naive-3Vehicle (DMSO)
SA30897420201210_Naive-1Vehicle (DMSO)
SA30897520201211_Naive-2Vehicle (DMSO)
Showing results 1 to 12 of 12


Collection ID:CO002965
Collection Summary:16D prostate cancer cells were cultured with vehicle or Enzalutamide for >2 months.
Sample Type:Cultured cells


Treatment ID:TR002981
Treatment Summary:Vehicle- and Enzalutamide-treated 16D cells were cultured in U13C-glucose containing media for 24 hours.

Sample Preparation:

Sampleprep ID:SP002978
Sampleprep Summary:Cell plates were placed on ice and quickly washed with ice-cold 0.9% (w/v) NaCl. Cells were immediately treated with 500 μL of ice-cold MeOH and 200 μL water containing 1 μg of the internal standard norvaline. Cells were then scraped and placed in 1.5 mL centrifuge tubes kept on ice. Next, 500 μL of chloroform was added, after which samples were vortexed for 1 minute and then spun at 10,000g for 5 minutes at 4C. The aqueous layer was transferred to a GC/MS sample vial and dried overnight using a refrigerated CentriVap.

Combined analysis:

Analysis ID AN004690
Analysis type MS
Chromatography type GC
Chromatography system Agilent 7890A
Column Agilent DB5-MS (30m x 0.25mm, 0.25um)
MS Type EI
MS instrument type GC-TOF
MS instrument name Agilent 5977B
Units abundance


Chromatography ID:CH003532
Instrument Name:Agilent 7890A
Column Name:Agilent DB5-MS (30m x 0.25mm, 0.25um)
Column Temperature:320
Flow Gradient:N/A (GC-MS)
Flow Rate:1 ml/min
Solvent A:N/A (GC-MS)
Solvent B:N/A (GC-MS)
Chromatography Type:GC


MS ID:MS004437
Analysis ID:AN004690
Instrument Name:Agilent 5977B
Instrument Type:GC-TOF
MS Type:EI
MS Comments:Data was analyzed using Agilent MassHunter software. Stable isotope tracing data was corrected for natural abundance of heavy isotopes with FluxFix software using a reference set of unlabeled metabolite standards2.